Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2/PSMA Bi-specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors
NCT05437315Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of bi-4SCAR-GD2/PSMA T cells in solid tumor, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
bi-4SCAR-GD2/PSMA T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05437315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437315.